PrairieView Partners LLC Has $40,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

PrairieView Partners LLC cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 31.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 100 shares of the pharmaceutical company’s stock after selling 45 shares during the quarter. PrairieView Partners LLC’s holdings in Vertex Pharmaceuticals were worth $40,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Czech National Bank increased its holdings in Vertex Pharmaceuticals by 6.2% during the fourth quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock worth $22,486,000 after buying an additional 3,260 shares during the last quarter. Whalen Wealth Management Inc. acquired a new stake in Vertex Pharmaceuticals during the third quarter worth about $662,000. Concord Wealth Partners grew its stake in Vertex Pharmaceuticals by 32.6% during the fourth quarter. Concord Wealth Partners now owns 3,508 shares of the pharmaceutical company’s stock worth $1,413,000 after buying an additional 862 shares in the last quarter. Mizuho Securities USA LLC boosted its stake in shares of Vertex Pharmaceuticals by 289.0% in the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after purchasing an additional 57,497 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in shares of Vertex Pharmaceuticals by 19.4% in the 4th quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock valued at $137,783,000 after purchasing an additional 55,739 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Down 0.4 %

Shares of VRTX opened at $453.20 on Thursday. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The business’s 50-day moving average price is $435.91 and its 200-day moving average price is $461.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post -1.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Piper Sandler lowered their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Cantor Fitzgerald restated an “overweight” rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday. Stifel Nicolaus raised their price objective on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research report on Monday, December 16th. Finally, Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and raised their price objective for the stock from $408.00 to $424.00 in a research report on Tuesday. Ten equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $505.96.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 310 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the completion of the transaction, the executive vice president now owns 64,021 shares in the company, valued at $29,438,776.43. This represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.